Chinese Pharmacological Bulletin 2003;0(10):-
Design and discovery of novel small-molecule inhibitor of CDK9
Li QIN ; Qing JI ; Yingdai GAO ; Juanni LIU ; Ming YANG ; Xiaofeng SHAO ; Dongsheng XIONG
Keywords
CDK9; homology modeling; small-molecule inhibitors; RNA polymerase Ⅱ; phosphorylation; tumor target; leading compound
Country
China
Language
Chinese
Abstract
Aim To look for novel small-molecule inhibitors of CDK9 through structure-based virtual screening and biological activity determination.Methods Homology modeling of CDK9 was based on the 3-D structure of other cyclin-dependent kinase family members,and then virtual screening by DOCK(molecular docking)of database of small molecule was carried on.MTT method was used in inhibition of tumor cell growth in vitro,while Western blot was used for further study of molecular mechanisms.Results From the top 1000 compounds with the best DOCK energy score,27 compounds were selected for biological assay based on the diversity of chemical structure and functional group.12 of 27 selected compounds showed significantly inhibition activity on tumor cell proliferation,and only one compound in 12 with half-maximum inhibition concentration(IC50)values less than 20 ?mol?L-1 named C-21 was selected for further molecular mechanism study.The western blotting data showed C-21 compound could effectively inhibit CDK9 from phosphorylating large subunit C-terminal of RNA polymerase Ⅱ in a dose-dependent manner.Conclusions Through homology modeling,virtual screening by computer,determination of biological activity and experimental studies of molecular mechanism,a new promising lead compound targeted for CDK9 was found and confirmed.
备案号: 11010502037788, 京ICP备10218182号-8)